• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

    12/2/25 8:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email

    BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or "the Company"), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025.

    Financial Highlights for the Nine Months Ended September 30, 2025

    • Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This was primarily due to a non-cash, bargain purchase gain recognized on the acquisition of Nodexus and Microsort businesses.

    • Basic earnings per share was $96.76 for the nine months ended September 30, 2025 while losses per share for the nine months ended September 30, 2024 was $205.97.
    • Net book value per share improved to $66.75 from negative net book value as of December 31, 2024, representing a significant balance sheet transformation driven by strategic acquisitions of high-value intellectual property assets.

    Business Highlights for the Nine Months Ended September 30, 2025

    The Company has made significant progress in executing its strategic pivot and diversification strategy throughout 2025. Key initiatives and achievements demonstrating this progress include:

    • Transformative Acquisitions: The Company completed two key acquisitions.
      • On February 28, 2025, the Company acquired the MicroSort® sperm-sorting technology, enhancing its capabilities in the fertility services market. The acquisition also resulted in a prior bargain purchase gain of $4.28 million based on an independent valuation report.
      • On July 29, 2025, the Company acquired advanced cytometry intellectual property and equipment from Nodexus. An independent valuation by a "big-four" accounting firm received in October 2025 confirmed a fair value of $17.9 million for the IP, resulting in a total bargain purchase gain of $19.16 million. This acquisition is central to the Company's pivot towards a high-margin, technology-licensing business model.
    • 2025 Debt Financing: On April 1, 2025, the Company entered into a Securities Purchase Agreement for the issuance of senior convertible notes with an aggregate principal amount of up to $28.8 million. The first tranche of $3.2 million was received on June 3, 2025, providing capital to fund our strategic initiatives.
    • Expansion into Digital Assets: The Company is actively building its digital asset portfolio, including a plan to invest in Solana (SOL). On June 2, 2025, the Company announced a plan to invest up to $30 million in SOL, and has, as of November 28, 2025, acquired 13,000.23 SOL. The Company has also been engaged to tokenize a $2 million private art collection and a $100 million tranche of gold-backed assets, representing new, potentially high-margin revenue streams.
    • Strategic Joint Venture in UAE Real Estate: Through its subsidiary, and as disclosed on October 8, 2025, the Company entered into a joint venture to develop a strategic plot of land in Ras Al Khaimah, UAE, securing a 60% ownership interest and is positioned to benefit from the project's gross revenue.
    • Proposed Reverse Merger: The Company is exploring a potential reverse merger with SAXA, Inc., which would provide access to a portfolio of mining assets, including a validated gold and silver mine.
    • Share Repurchase Program: In November 2025, the Company's Board of Directors authorized a share repurchase program of up to $2 million over 24 months, reflecting management's confidence in the intrinsic value of the Company.
    • Reverse Stock Split: On November 10, 2025, the Company announced a one-for-five reverse stock split of its issued and unissued shares (the "Reverse Stock Split"). The Reverse Stock Split became effective on Monday, December 1, 2025 and the Company's Class A Ordinary Shares began trading on the Nasdaq Capital Market on a split-adjusted basis at the opening of market on December 1, 2025.

    Management Commentary

    Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, "The nine months ended September 30, 2025 represent an important period for NewGen, with net income of $17.5 million compared to a net loss in the prior year. This improvement was driven by our strategic focus on acquiring high-value intellectual property. The acquisition of Nodexus business including but not limited to advanced cytometry IP generated a bargain purchase gain and increased our net asset value per share to $66.75, positioning us as a technology-driven company with a licensing model that we can scale globally."

    "Beyond this core transformation, we embraced the execution of a diversified growth strategy across multiple high-potential sectors. Our digital asset initiatives include strategic Solana treasury positioning and exclusive tokenization mandates in art- and gold-backed assets, representing significant new revenue opportunities. Meanwhile, our UAE real estate joint venture provides direct access to promising Middle Eastern development projects with attractive revenue-sharing terms. Combined with our newly reinforced balance sheet, we believe this unique combination of proprietary technology assets, strategic market positioning, and strong execution creates compelling long-term value for our shareholders."

    Nine Months Ended September 30, 2025 Financial Results

    • Revenues: Total revenues were $3.3 million for the nine months ended September 30, 2025, compared to $4.2 million from the same period 2024.

    • Cost of Revenues: Cost of revenues was unchanged at $2.9 million, compared to the previous year.
    • Total Other Income: Total other income, net, was $23.20 million for the nine months ended September 30, 2025, a substantial improvement from other losses, net, $346,748 in the prior year period. This was primarily due to a non-cash, bargain purchase gain of $23.44 million recognized on the acquisition of Nodexus and Microsort businesses including but not limited to its intellectual property and trademarks based on two independent valuation reports.
    • General and Administrative Expenses: General and administrative expenses were $5.7 million, compared to $1.1 million for the nine months ended September 30, 2024. The increase was primarily attributable to costs associated with supporting the Company's expanding strategic initiatives and corporate development activities.
    • Net Income: Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This result was primarily driven by a $23.44 million gain from bargain purchases on acquisitions.

    About NewGenIvf Group Limited

    NewGenIvf Group Limited (NASDAQ:NIVF) is a tech-forward, diversified, multi-jurisdictional company transforming industries through innovative solutions. The Company is strategically pivoting from its foundation in fertility services to a technology-driven model centered on the licensing of proprietary reproductive technologies. This core is augmented by strategic growth vectors in digital asset management, including tokenization services and a Solana treasury strategy, and real estate development through a joint venture in the UAE. NewGen is focused on building a high-growth, diversified ecosystem that leverages blockchain technology and strategic acquisitions to drive long-term shareholder value.

    Safe Harbor Statements

    This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "going forward," "outlook," and similar statements. Forward-looking statements in this 6-K include, but are not limited to, statements regarding: (i) the Company's strategic pivot to a technology-licensing business model and its ability to generate licensing revenue from acquired intellectual property; (ii) plans to invest in digital assets, including Solana, and the Company's digital asset treasury strategy; (iii) tokenization services and revenue opportunities related to art collections and gold-backed assets; (iv) the anticipated benefits and revenue potential from the UAE real estate joint venture; (v) the potential reverse merger with SAXA, Inc and access to mining assets; (vi) the Company's diversified growth strategy and ability to execute across multiple business sectors; and (vii) the Company's financial condition, liquidity, and ability to fund its strategic initiatives.

    These forward-looking statements are based on management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties, and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: (i) the Company's ability to successfully commercialize and license acquired intellectual property; (ii) uncertainty regarding the actual fair value of acquired intangible assets and potential future impairment charges; (iii) risks that independent valuations may not reflect actual market value or revenue generating potential; (iv) regulatory requirements and restrictions affecting reproductive technologies in various jurisdictions; (v) extreme volatility in digital asset markets, including Solana; (vi) the Company's limited operating history in multiple new business segments and unproven business models; (vii) management's ability to effectively oversee business operations across multiple jurisdictions; (viii) uncertainties regarding the ability to fund, develop, obtain permits and complete the UAE real estate project; and (ix) the Company's ability to secure additional financing on favorable terms or at all. The risks and uncertainties described above are not exhaustive. Additional risks and uncertainties not presently known to the Company may also adversely affect the Company's business, financial condition, results of operations, and prospects. These factors may cause the Company's actual results, performance, or achievements to differ materially from those in the forward-looking statements. Investors are urged to carefully review and consider the various disclosures made by the Company in this release and in the Company's periodic reports filed with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required under applicable law. Readers should not rely upon the information in this news release as current or accurate after its publication date.

    For more information:

    Investor Relations Contact

    ICR, LLC

    Robin Yang

    Phone: +1 (212) 537-4406

    Email: [email protected]





    NEWGENIVF GROUP LIMITED

    UNAUDITED CONSOLIDATED BALANCE SHEETS

    (Stated in US Dollars)




      September 30,  December 31, 
      2025  2024 
      (unaudited)  (audited) 
    ASSETS      
    Current assets      
    Cash and cash equivalents $295,289  $457,740 
    Accounts receivable, net  185,907   49,245 
    Inventories  86,977   80,813 
    Deposits, prepayments and other receivables, net  951,046   195,446 
    Deposit with a digital asset trading platform  2,674,042   1,000,000 
    Receivable from agents  1,272,640   1,191,795 
    Prepayments  ---   197,706 
    Due from related parties  89,973   — 
    Total current assets  5,555,874   3,172,745 
             
    Non-current assets        
    Plant and equipment, net  329,360   273,096 
    Right-of-use assets, net  846,335   98,570 
    Intangible assets  24,242,555   --- 
    Investment in Artwork  270,000   --- 
    Financial Assets  262,712     
    Deferred legal and professional fees  196,623   --- 
    Other receivable, deposit and other receivables, net  3,854,609   33,333 
    Taxes recoverable  326   --- 
    Total non-current assets  30,002,520   404,999 
    TOTAL ASSETS $35,558,394  $3,577,744 
             
    LIABILITIES AND SHAREHOLDERS' EQUITY        
    Current liabilities        
    Accounts payable $797,718  $1,298,964 
    Accrued liabilities and other payables  450,341   500,729 
    Contract liabilities  67,401   63,489 
    Due to related parties  ---   154,453 
    Operating lease liabilities, current  305,518   108,526 
    Convertible notes  --   82,447 
    Promissory note  --   500,000 
    Taxes payable  --   11,746 
    Total current liabilities  1,620,978   2,720,354 
    Non-current liabilities        
    Operating lease liabilities, non-current  298,081   10,231 
    Convertible notes, non-current  4,900,000   2,328,916 
             
    Total non-current liabilities  5,198,081   2,339,147 
    Total liabilities $6,819,059  $5,059,501 
             
    Shareholders' equity        
    Ordinary shares, no par value, unlimited authorized shares and 430,540* and 2,030* shares issued and outstanding as of September 30, 2025 and December 31, 2024 respectively  —   — 
    Subscription receivable  —   (204,000)
    Additional paid-in capital  13,063,507   122,505 
    Retained Earnings / (Accumulated deficit)  16,562,336   (985,994)
    Accumulated other comprehensive (loss) income  (249,711)  18,875 
    Equity attributable to the shareholders of the Company  29,376,132   (1,048,614)
    Non-controlling interests  (636,797)  (433,143)
    Total shareholders' equity  28,739,335   (1,481,757)
             
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $35,558,394  $3,577,744 



    The accompanying notes are an integral part of these consolidated financial statements.

    *The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in February 2025 of 1 share for every 20 existing shares issued, in May 2025 of 1 share for every 10 existing share issued, in August 2025 of 1 share for every 5 shares issued and in December 2025 of 1 share for every 5 shares issued respectively.



    NEWGENIVF GROUP LIMITED

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE (LOSS) INCOME

    (Stated in US Dollars)





      Nine Months Ended 
      September 30,

    2025
      September 30,

    2024
     
    Revenues $3,301,879  $4,159,763 
    Cost of revenues  (2,870,058)  (2,872,004)
    Gross profit  431,821   1,287,759 
             
    Operating expenses        
    Selling and marketing expenses  (494,388)  (192,276)
    General and administrative expenses  (5,690,300)  (1,166,858)
             
    Total operating expenses  (6,184,688)  (1,359,134)
             
    Operating income (loss)  (5,752,867)  (71,375)
             
    Other income (expenses), net        
    Other income, net  23,370,460   8,404 
    Interest income  2,003   2,399 
    Interest expense  (173,583)  (357,551)
    Total other income (expenses), net  23,198,880   (346,748)
             
    Income (loss) before taxes  17,446,013   (418,123)
    Provision for income taxes  ---   --- 
    Net income (loss)  17,446,013   (418,123)
    Less: net loss attributable to non-controlling interests  (102,317)  (1,723)
    Net income (loss) attributable to the shareholders of the Company $17,548,330   (416,400)
             
    Other comprehensive (loss) income        
    Foreign currency translation adjustment  (369,923)  13,879 
    Total comprehensive income (loss)  17,076,090   (404,244)
    Less: total comprehensive loss attributable to non-controlling interests  (203,654)  1,498 
             
    Total comprehensive income (loss) attributable to the shareholders of the Company $17,279,744   (405,742)
             
    Earning per share – basic $96.76   (205.97)
    Basic weighted average shares outstanding*  180,304   2,030 



    The accompanying notes are an integral part of these consolidated financial statements.

    *The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in February 2025 of 1 share for every 20 existing shares issued, in May 2025 of 1 share for every 10 existing share issued, in August 2025 of 1 share for every 5 shares issued and in December 2025 of 1 share for every 5 shares issued respectively.


    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen to Exercise Option to Convert Ras Al Khaimah Joint Venture into Joint Development, Projected to Boost Profits from US$67 Million to US$123 Million

    BANGKOK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced its intention to exercise an option under its joint venture agreement ("JVA") with BNW Real Estate Development LLC ("BNW") to convert the Ras Al Khaimah development project from a Joint Venture structure into a Joint Development structure, while maintaining the existing shareholding of the special purpose vehicle ("SPV"). This strategic conversion is expected to enhance NewGen's profit entitlement in the flagship Ras Al Khaimah Beach

    12/12/25 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

    BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or "the Company"), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025. Financial Highlights for the Nine Months Ended September 30, 2025 Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This was primarily due to a non-cash, bargain purchase gain recognized on the acquisition of Nodexus and Microsort businesses.Basic

    12/2/25 8:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Announces Up to US$2 Million Share Repurchase Program

    BANGKOK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its Board of Directors (the "Board") has authorized a share repurchase program under which the Company may repurchase up to US$2 million of its outstanding Class A ordinary shares over the next 24 months ("Share Repurchase Program"). The Company plans to adopt and implement this Share Repurchase Program in accordance with applicable rules and requirem

    11/10/25 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    12/2/25 8:01:34 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/25/25 4:00:29 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/10/25 4:00:19 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care